DefEYE Inc. (DefEYE), a privately held ophthalmic biologics company with a portfolio of decellularized biologic solutions, announced its launch as an independent company, effective October 1, 2025. The company previously operated as Verséa Ophthalmics, Inc., a subsidiary under the Verséa Health, Inc. holdings company.
According to a company press release, DefEYE will be led by a seasoned leadership team with expertise in ophthalmic therapeutics, diagnostics, and commercialization. Rob Sambursky, MD, a Wills Eye trained corneal specialist and serial entrepreneur with a track record of leading companies across both diagnostic and therapeutic platforms, has been appointed chief executive officer. He will be joined by Robert Glashow, a finance and operations executive with experience guiding initial public offerings, mergers, and acquisitions, who will serve as chief financial officer.
In addition, Rahim Hirji, RPh, will serve as senior vice president of marketing and brings broad commercial experience, including marketing, market access, professional relations, and successful product launches. Tyler Johnson, VP of Market Development and Rebecca Chandler VP of Strategic Accounts will round out the commercial leadership team.
According to the press release, DefEYE secured exclusive commercial rights to a portfolio of decellularized biologics, including the Biovance franchise of products which includes Biovance 3L Ocular and Biovance amniotic 2 decellularized basement membrane products. Additionally, DefEYE has access to commercial rights to additional decellularized human placenta-derived biologics.
Biovance and Biovanced 3L Ocular are decellularized basement membranes used to elevate the management of ocular surface disease and ocular surgery. Biovance 3L Ocular has a tri-layer architecture containing a preserved natural epithelial basement membrane and intact extracellular matrix structure. As a barrier membrane, Biovance 3L Ocular is intended to protect the underlying tissue and preserve tissue plane boundaries. Applications include corneal and conjunctival-related injuries or defects such as corneal epithelial defects, pterygium repair, fornix and reconstruction.